Overall, the ablating PANX1 function, pharmacologically or genetically, may constitute a novel multi-pronged therapeutic target for metastatic breast cancer by reverting EMT and decreasing the metastatic ability and invasiveness of breast cancer cells. The gene discussed is PANX1; the disease is breast cancer.